ALAMEDA, Calif.
AgeX Therapeutics, Inc. (AgeX), a subsidiary of BioTime, Inc. (NYSE American: BTX), announced today that Chief Executive Officer Michael D. West, Ph.D., who also serves as Co-CEO of BioTime, is giving an interview as part of The Economist magazine’s conference, “The Business of Longevity: Health Innovation for An Ageing World,” on Friday, October 27 in Hong Kong.
In a session titled “Special Interview: The Science of Ageing,” Dr. West will be interviewed by Charles Goddard, editorial director Asia Pacific from The Economist Intelligence Unit, about the current state of longevity research and development. The session descriptor follows:
“There is much excitement about the next big breakthroughs in longevity science, which will come in such areas as tissue engineering, the application of machine learning to biological data, and halting the ageing process with stem cells and gene therapy. But when are those breakthroughs likely to occur? In this interview, a leading thinker will explore the scientific and medical innovations that could extend human life even further.”
About AgeX Therapeutics
AgeX Therapeutics, Inc., a subsidiary of BioTime, Inc. (NYSE American: BTX), is a biotechnology company applying technology relating to cellular immortality and regenerative biology to aging and age-related diseases. The company has three initial areas of product development: pluripotent stem cell-derived brown adipocytes (AGEX-BAT1); vascular progenitors (AGEX-VASC1); and induced Tissue Regeneration (iTR). Initial planned indications for these products are Type 2 diabetes, cardiac ischemia, and cancer respectively. For more information, please visit www.agexinc.com or connect with the company on Twitter or Facebook.
About BioTime
BioTime is a late stage clinical biotechnology company focused on developing and commercializing products addressing degenerative diseases. The Company’s current clinical programs are targeting three primary sectors, aesthetics, ophthalmology and cell/drug delivery. Its clinical programs are based on two platform technologies: pluripotent cells, which can become any type of cell in the human body, and cell/drug delivery. Renevia®, a cell delivery product, met its primary endpoint in an EU pivotal trial for the treatment of facial lipoatrophy in HIV patients earlier this year. Submission for approval of Renevia® is expected later this year, with an anticipated commercial launch in 2018. OpRegen®, a retinal pigment epithelium transplant therapy, is in a Phase I/IIa multicenter trial for the treatment of dry age-related macular degeneration, the leading cause of blindness in developing countries. BioTime also has significant equity holdings in two publicly traded companies, Asterias Biotherapeutics, Inc. (NYSE American: AST) and OncoCyte Corporation (NYSE American: OCX), and a private company, AgeX Therapeutics, Inc.
BioTime common stock is traded on the NYSE American and TASE under the symbol BTX. For more information, please visit www.biotime.com or connect with the company on Twitter, LinkedIn, Facebook, YouTube, and Google+.
To receive ongoing BioTime corporate communications, please click on the following link to join the Company’s email alert list: http://news.biotimeinc.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20171026005328/en/
CONTACT
Investor Contact for BioTime:
David Nakasone, 510-871-4188
Dnakasone@biotimeinc.com
or
Media
Contact for AgeX:
Gotham
Communications, LLC
Bill
Douglass, 646-504-0890
bill@gothamcomm.com
